Menthol
As of the edition of 20 October 2026, Menthol is a small molecule: marketed, first approved in 1990 (CA); acts on TRPA1 and TRPM8.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2008
- Kind
- Small molecule
- Brand name
- Salonpas
- First approved
- 31 December 1990 (CA)
- Approvals on record
- 10 in 2 regions
- Holder of the most recent approval
- Sanofi; 5 holders in all
- Registered trials
- 35, 1 stopped early
- Disease areas
- Lungs and airways; Nervous system; Digestive system; Ear, nose and throat; Cancer; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
3 company-target rows on route B because of this drug.
Companies on route B for this drug
In the product3 company-target rows are on route B because of Menthol.
See the 3 company-target rows on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 16 | 11 | 3 | 0 |
| Phase 1 | 7 | 5 | 1 | 0 |
| Phase 2 | 5 | 4 | 0 | 1 |
| Phase 3 | 6 | 5 | 0 | 0 |
| Phase 4 | 1 | 1 | 0 | 0 |
| All trials | 35 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Sanofi | Applicant | 1999 to now |
| Reckitt Benckiser | Later holder | 2012 to now |
| Johnson & Johnson | Later holder | 2015 to now |